The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.
Tenaya Therapeutics, a US-based heart disease therapy developer backed by internet and technology group Alphabet, listed in a $180m initial public offering on the Nasdaq Global Select Market on Thursday.
The offering involved the company issuing 12 million shares at $15 each, in the middle of the $14 to $16 range, and they opened at $19.50 apiece prior to closing at $15.35 on the first day of trading.
Founded in 2016, Tenaya is developing treatments for heart-related conditions with…
